DERMATITIS, ATOPIC

This study follows 858 people with atopic dermatitis (eczema) who are starting treatment with Dupixent. Researchers track how well the drug works and any side effects over time in everyday medical practice. Participants include teens and adults, and the goal is to understand long…

This study tests whether a drug called amlitelimab can keep eczema under control for a full year in people aged 12 and older with moderate-to-severe atopic dermatitis. Participants who already responded to treatment in an earlier study will either continue receiving the drug ever…

This study tests the drug lebrikizumab in 520 adults and teens with moderate-to-severe eczema (atopic dermatitis). The first part looks at how well the drug improves skin symptoms after 24 weeks. The second part compares a new dosing schedule (one injection every 12 weeks) to the…

This study tests the long-term safety and effectiveness of a new drug called amlitelimab for people aged 12 and older with moderate to severe atopic dermatitis (eczema). Participants receive the drug for up to 5 years and are monitored for side effects and how well the drug contr…

This study looks at how well dupilumab (Dupixent) works over 2 years in children aged 6 to 14 with moderate-to-severe atopic dermatitis (eczema). About 48 kids will receive the drug and researchers will measure skin barrier function and track side effects. The goal is to see if l…

This study looks at the long-term safety and effectiveness of amlitelimab, an injected drug for moderate to severe eczema (atopic dermatitis). It includes over 1,600 people who have already taken amlitelimab in earlier studies. Some participants will stop treatment temporarily to…

This study tests a new medicine called 611 in 124 children and teens (ages 6 to 17) with moderate to severe eczema. The goal is to see if it is safe and how well it works to reduce skin symptoms like redness and itching. Participants receive the drug as an injection, and research…

This study tests a new medication called JNJ-95475939 in 256 adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, itching, and rash better than a placebo. Participants receive the drug or placebo for 12 weeks, and doctors measu…

This study tests a new medicine, BAT6026, in 33 adults with moderate to severe eczema that creams couldn't control. The goal is to see if it safely reduces skin redness, itching, and rash by at least 75% after 4 doses. Researchers compare different doses to a placebo to find the …

This study was designed to check how well JAK inhibitors work and how safe they are for adults with moderate-to-severe eczema. It planned to track skin improvement, itching, sleep loss, and side effects in a real-world setting in France. However, the study was withdrawn before en…

This study follows 262 people with moderate to severe atopic dermatitis (eczema) who previously received an experimental stem cell treatment called FURESTEM-AD. The goal is to check for any long-term side effects and see how well the treatment holds up over time. Participants are…